Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: DBS Bank
$58.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biosensors International Group Ltd announces IDE approval for Biofreedom U.S. trial


Monday, 5 May 2014 08:06am EDT 

Biosensors International Group Ltd:Says U.S. Food and Drug Administration (FDA) recently granted conditional Investigational Device Exemption (IDE) approval for U.S.-based clinical trial of BioFreedom(tm) polymer-free drug-coated stent (DCS) system.BioFreedom U.S. IDE Feasibility Trial is designed to collect additional safety and effectiveness data for BioFreedom system and to support a future pivotal IDE study.Company believes this is first clinical study within U.S. evaluating polymer-free DCS, and also first U.S. clinical study of device benefitting from use of Biolimus A9(BA9) drug. 

Company Quote

0.71
-0.0050 -0.70%
16 Sep 2014